Search
Liquidia Corp
LQDAAdd to Watchlist
78.930USD
-0.390-0.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
6.97BMarket Cap
315.43P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.49%
5 Days
+0.97%
1 Month
+41.73%
6 Months
+151.37%
Year to Date
+128.85%
1 Year
+547.50%
Key Figures
79.960Open
80.470High
1.41MVolume
315.43P/E TTM
11.70P/E Dynamic
--Dividend TTM
1.59%Turnover Ratio
79.320Prev. Close
77.250Low
90.74MTurnover
LossP/E Static
64.19P/B
0.00%Div Yield TTM
7.09%ROA
46.67052wk High
1.10Volume Ratio
-130.39MNet Profit
88.31MShares
0.2502EPS TTM
0.41Beta
28.18%ROE
11.26052wk Low
4.06%Amplitude
91.08%Gross Margin
6.97BMarket Cap
6.88Reward/Risk
3.90%Risk Rate
TradingKey Stock Score of Liquidia Corp
Currency: USD Updated: 2026-07-02Key Insights
Liquidia Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 73.75.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Liquidia Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Liquidia Corp Highlights
StrengthsRisks
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 805.31% year-on-year.
Overvalued
The company’s latest PE is 315.43, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 65.17M shares, decreasing 9.44% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 34.18K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.59.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
73.750
Target Price
-7.02%
Upside Space
Liquidia Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Liquidia Corp Info
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Ticker SymbolLQDA
CompanyLiquidia Corp
CEOJeffs (Roger A)
Websitehttps://www.liquidia.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Liquidia Corp (LQDA)?
The current price of Liquidia Corp (LQDA) is 78.93.
What is the symbol of Liquidia Corp?
The ticker symbol of Liquidia Corp is LQDA.
What is the 52-week high of Liquidia Corp?
The 52-week high of Liquidia Corp is 46.67.
What is the 52-week low of Liquidia Corp?
The 52-week low of Liquidia Corp is 11.26.
What is the market capitalization of Liquidia Corp?
The market capitalization of Liquidia Corp is 7.02B.
Is Liquidia Corp (LQDA) currently rated as Buy, Hold, or Sell?
According to analysts, Liquidia Corp (LQDA) has an overall rating of Buy, with a price target of 73.75.
What is the Earnings Per Share (EPS TTM) of Liquidia Corp (LQDA)?
The Earnings Per Share (EPS TTM) of Liquidia Corp (LQDA) is -0.80.